middle.news
Anteris Advances DurAVR Trial with $320M Raise and Medicare Coverage
8:25am on Wednesday 12th of August, 2026 AEST
•
Healthcare
Read Story
Anteris Advances DurAVR Trial with $320M Raise and Medicare Coverage
8:25am on Wednesday 12th of August, 2026 AEST
Key Points
H1 2026 revenue up 28% to $1.5 million
Loss after tax widened 20% to $51.7 million
R&D expenses surge with manufacturing scale-up and PARADIGM Trial
Raised $320 million in January via public offering and Medtronic placement
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Anteris Technologies Global (ASX:AVR)
OPEN ARTICLE